Shire, and Santaris Extend Alliance to Develop LNA-drugs - - BioPharm International

ADVERTISEMENT

Shire, and Santaris Extend Alliance to Develop LNA-drugs



Santaris Pharma, a biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has extended its existing partnership with Shire for treatments for rare genetic diseases. 

Under the terms of the extended agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development.  Santaris will receive an upfront payment and, consistent with the initial agreement, is eligible for research support, pre-clinical, clinical, and sales milestones, as well as royalties on each product emerging from the collaboration.

Source: Santaris Pharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here